anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The Education and Career Task Force of the Young Epilepsy Section-Italy focuses on educational and career development needs of young Italian epileptologists. Two surveys were developed (pre- and post COVID-19 pandemic) in order to identify the needs of members of the Lega Italiana Contro l'Epilessia under 40 years of age.
METHODS: The first was distributed during the 42nd National Congress (Rome, June 5-7, 2019); the second during the 45th National Congress (Padova, June 8-10, 2022) and subsequently by e-mail until July 9, 2022. Data from the 2019 survey were analyzed descriptively. Data from the 2022 survey were further analyzed with Pearson's chi-square test to establish if gender, field of clinical practice, and professional role were associated with different needs.
RESULTS: Sixty surveys were completed in 2019 and 69 in 2022. Attendance to courses and congresses as the preferred way to keep medical knowledge updated reduced between 2019 and 2022. The reason was different between trainees (mostly elevated costs) and early-career consultants (mostly organizational issues) (p = 0.005). The main needs for improvement also diverged: trainees indicated differential diagnosis and diagnostic approach to the first seizure while consultants indicated diagnostic approach to genetic epilepsies (p = 0.004); in the genetic field, priority needs were selection of genetic investigations for trainees versus genotype-phenotype correlations for consultants (p = 0.022). The field of practice (pediatric vs. adult) also impacted on the main needs for improvement that is, acquisition of expertise in neuroradiology and drug therapy for pediatric versus genetics for adult neurology trainees or consultants (p = 0.018); in the clinical area, differential diagnosis and approach to the first seizure versus status epilepticus (p = 0.027); in the genetic field, precision medicine versus genotype-phenotype correlations (p = 0.034). No differences were found based on gender.
SIGNIFICANCE: The surveys identified different needs based on professional role and discipline.
PLAIN LANGUAGE SUMMARY: The Education and Career Task Force of the Young Epilepsy Section-Italy (YES-I) launched two surveys among young Italian epileptologists. Our research shows that the educational and professional needs of young Italian epileptologists vary based on their job role and field of practice, but not on gender. Their preference for on-site congresses and courses reduced after the pandemic, and the main reason is linked to financial constraints for trainees and to organizational issues for consultants. The main expectation toward YES-I is to receive support for education and career development. Thus, we collected useful suggestions on how to organize our future YES-I activities.
There is no treatment for acute aortic dissection (AAD) targeting inflammatory cells. We aimed to identify the new therapeutic targets associated with inflammatory cells. We characterized the specific distribution of myeloid cells of both human type A AAD samples and a murine AAD model generated using angiotensin II (ANGII) and β-aminopropionitrile (BAPN) by single-cell RNA sequencing (scRNA-seq). We also examined the effect of an anti-interleukin-1β (IL-1β) antibody in the murine AAD model. IL1B+ inflammatory macrophages and classical monocytes were increased in human AAD samples. Trajectory analysis demonstrated that IL1B+ inflammatory macrophages differentiated from S100A8/9/12+ classical monocytes uniquely observed in the aorta of AAD. We found increased infiltration of neutrophils and monocytes with the expression of inflammatory cytokines in the aorta and accumulation of inflammatory macrophages before the onset of macroscopic AAD in the murine AAD model. In blocking experiments using an anti-IL-1β antibody, it improved survival of murine AAD model by preventing elastin degradation. We observed the accumulation of inflammatory macrophages expressing IL-1β in both human AAD samples and in a murine AAD model. Anti-IL-1β antibody could improve the mortality rate in mice, suggesting that it may be a treatment option for AAD.
Abstract The present invention relates to a topic composition comprising carbon dioxide (CO2). This can be in the form of a salve, ointment, lotion, aerosol, liniment, gel, paste, flexible plate or cataplasm fulfilling the above mentioned needs. The treat- ment with this new composition comprising CO2, will be locally and hereby efficient, when using this composition and it will not give rise to changes in pH on the skin. To work efficiently the composition is preferably covered to minimise the amount of CO2 to evaporate into the air. The composition is preferably used in combination with a cover material/plaster. Also claimed is a plaster containing the composition and a container containing the composition.
A 56-year-old female patient had a hip operation one year previously and experienced her first dislocation two months postoperatively. The patient underwent closed reduction three times. The patient presented to us due to a fourth hip dislocation that had occurred one month previously. Hip X-ray images revealed acetabular component malposition, with an 80-degree inclination and 20 degrees of cup anteversion with a posterior hip dislocation. The investigators treated the patient via pelvic osteotomy, using a modified Stoppa approach to reduce acetabular inclination. The patient had no dislocation at the 2-year follow-up. At the last follow-up, the Harris Hip Score was 85.
Children weighing 10 to less than 14 kg at study entry. These children received 4 dispersible tablets of ABC/DTG/3TC daily while weighing 10-\<14 kg; as their weight increased, they received higher doses consistent with their new weight band.
OBJECTIVE: Constipation is more common in patients with mental disorders than in the general population. However, its frequency in hospitalized patients, its association with drugs and how teams become aware of it and take care of it are not fully identified.
METHOD: The retrospective study included 141 male and 127 female new patients admitted for routine treatment at France's largest psychiatric hospital between November 15 and December 11, 2017. A physician reviewed electronic medical records to diagnose constipation and record variables of interest: socio-demographic factors, diagnosis, drugs prescribed and taken. We calculated an anticholinergic impregnation score (AIS) for each patient by using a validated French scale. Patients were then classified into two groups by state of constipation defined by the physician. Univariate and multivariate analyses were used to study the frequency of constipation, factors associated with it and its management.
RESULTS: The prevalence of constipation was 38% (95% CI 32-44). Associated factors were taking antipsychotics and the burden of anticholinergic treatment. On multiple regression analysis, the only remaining factor was anticholinergic treatment: AIS≥5 was associated with constipation (odds ratio 1.80 [95% CI 1.07-3.14], P=0.027). Only 44.0% of patients were prescribed a preventive laxative, systematically in half of the cases. Above all, only 11.2% were administered this laxative (i.e., 25% of that prescribed). Digestive transit was poorly recorded in the table of constants (34.7%). We found one case of sub-occlusion as a severe case.
CONCLUSION: Constipation is common in psychiatric inpatients. The more the patient is prescribed drugs with a pronounced anticholinergic effect, the greater the risk. Alongside the preventive measures common to all psychiatric patients which must be promoted (concerning diet, physical activity, etc.), polymedication with this type of anticholinergic must be better monitored to prevent complications: prescription and administration of a preventive laxative, monitoring transit in the table of constants. Thus, a better knowledge of the subject and specific training are essential.
The invention discloses a preparation method of an ilex hainanensis merr anti-hypertension oral liquid. Ilex hainanensis merr has the efficacies of clearing away heat and toxic material, calming the liver and suppressing yang and therefore can be used for treating patients suffering from hypertension, hyperlipidemia, and the above troubles. Clinical assays prove that the oral liquid has obvious curative effect. However, as the ilex hainanensis merr is prepared into tablets at present and the raw material used in the production process of the tablets is extractum, the tablet hardly reaches the technical requirements on disintegration time, takes effect slowly and low in bioavailability per unit time. By adopting the preparation method disclosed by the invention, the ilex hainanensis merr is prepared into the oral liquid; the clinical assays prove that 239 cases in the hypertension group are cured with the total effective rate being 93.53%, and in a total number of 233 hyperlipemia patients, 120 patients from 165 high-cholesterol patients are cured with the total effective rate being 92.72%. Compared with the tablet, the oral liquid has certain superiority and is free of other side effects. The oral liquid prepared by adopting the preparation method disclosed by the invention can take effect quickly, has high bioavailability, and can be absorbed quickly in gastrointestinal tract, generally can take effect in 3-10 minutes after being taken and can be well absorbed; moreover, the oral liquid can take effect more quickly than the tablets.
Drug-related fatalities in the EU are predominantly associated with opioids. MDMA (Ecstasy) consumption results in fewer lethal intoxications despite its widespread use. This study investigates MDMA-related fatalities, focusing on enantiomer ratios of MDMA and its metabolite MDA to explore the role of metabolism in fatal outcomes. MDMA induces euphoria, increased empathy, and physiological effects such as tachycardia, hypertension, and hyperthermia. Metabolism mainly involves CYP1A2 and CYP2D6, with polymorphism of the latter influencing metabolism rates. Our institute observed several MDMA-related fatalities, which prompted an investigation into the potential role of inefficient drug metabolism in these cases. A novel quantitative chiral analysis method was developed and validated for MDMA, MDA, amphetamine and methamphetamine enantiomers in human blood. Analysis of post mortem blood samples from eleven MDMA-related fatalities exhibited a wide range of concentrations and enantiomer ratios. Variability in R/S MDMA ratios, however, could be linked to the time period of metabolism. Hair analysis revealed high MDMA concentrations in all segments, irrespective of prior drug abuse anamnesis. Therefore, hair analysis may not be suitable for the assessment of past drug use in ecstasy-related fatalities. The results indicated that elevated levels of the MDMA enantiomer are correlated with longer survival times in cases of intoxication. However, there was no clear evidence for slowed MDMA metabolism as a cause of lethal intoxications. While challenges remain due to the diversity of cases, this study contributes valuable insights into ecstasy intoxications, aiding future interpretation of post mortem analysis.
A stem cell preparation for treating nerve injury and a preparation method thereof. The invention relates to the stem cell preparation and the preparation method thereof and provides the stem cell preparation for treating the nerve injury and the preparation method thereof. The stem cell preparation includes: mesenchymal stem cells, a trehalose solution, an epidermal growth factor and a basic fibroblast growth factor. The preparation method comprises following steps: (1) performing separation and purification to the mesenchymal stem cells, performing serial subcultivation to obtain the mesenchymal stem cells in P3-P5 generations; (2) performing detections of virus, sterilization, immunophenotype, cell viability and differentiation function to the mesenchymal stem cells in the P3-P5 generations; and (3) collecting and purifying the mesenchymal stem cells, re-suspending the mesenchymal stem cells in the trehalose solution, and adding the epidermal growth factor and the basic fibroblast growth factor to obtain the stem cell preparation. In the invention, the mesenchymal stem cells are wide in sources without damages on donors. The stem cell preparation is used for treating the nerve injury.
A maximal isometric muscle contraction of the quadriceps will be used to examine neural and peripheral contributions to quadriceps strength. Neural influences will be quantified using the interpolated twitch technique (voluntary activation) and early RTD. Peripheral influences will be quantified by examining the stimulus-evoked torque with the quadriceps relaxed (resting twitch) and late RTD. Knee joint biomechanics during treadmill walking and running will include sagittal plane (flexion, extension) movement variability (Lyapunov Exponent and approximate entropy), peak knee flexion angle, and peak external knee flexion and adduction moments. Additionally, the clinical relevance of impairments in the ACL reconstruction group will be determined by examining the relationship with performance on jumping tasks and patient function (secondary outcomes).

The progressive strengthening program will be performed for 6 weeks and emphasize development of strength and power. Feasibility will be established if the researchers can recruit up to 8 participants and retain at least 80% over the 3 week intervention program. The researchers will determine effect sizes for changes outcome measures.
BACKGROUND: The International Survey of People living with Chronic Conditions (OECD-PaRIS survey), aims to systematically gather patient-reported experiences (PREMs) and - outcomes (PROMs) and potential predictors for these outcomes for persons with chronic conditions as well as information from professionals about health care provided. In such patient surveys, the advantages of a multilevel (nested) approach in which patients are sampled 'within providers' need to be balanced against the potential for bias if patient populations from participating GPs significantly differ from those of non-participating GPs. The objective was to assess the effects of general practitioner (GP) non-participation on the representativeness of the Norwegian patient data of the International Survey of People living with Chronic Conditions (OECD-PaRIS survey).
METHODS: To test all aspects of the first main PaRIS survey, it was preceded by a field trial which this paper reports on the Norwegian part of. For the Norwegian part of the field trial in 2022, we randomly sampled and surveyed 75 GPs and 125 patients 45 years and older for each GP, regardless of whether their GP were also participating in the study. GPs were sampled from a national register that included all GPs. The surveys were primarily digital, but we sent postal questionnaires to non-digital patients and non-responding digital patients. We compared GP and patient characteristics as well as patient-reported experiences and outcomes according to GP participation status in bivariate analysis, supplemented with multiple linear regressions with PREMs/PROMs as dependent variables and participation status as independent adjusting for significant patient factors.
RESULTS: 17 of 75 sampled GPs participated (22.7%), of which 993 of 2,015 patients responded (49.3%). 3,347 of 7,080 patients of non-responding GPs answered (47.3%). Persons with chronic conditions from participating GPs reported significantly better patient-centred coordinated care (p = 0.017), overall experiences with the GP office the last 12 months (p = 0.004), mental well-being (p = 0.039) and mental health (p = 0.013) than patients from non-participating GPs. The raw differences between participating and non-participating GPs on patient-reported experiences and - outcomes varied from 1.5 to 2.9 points on a 0-100 scale, and from 2.2 to 3.0 after adjustment for case-mix.
CONCLUSIONS: The Norwegian field trial indicates that estimates based on participants in the PaRIS survey may modestly overestimate patient-reported experiences and -outcomes at the aggregated level and the need for more research within and across countries to identify and address this potential bias.
PURPOSE:To collect the titled novel antibiotic from a culture, by cultivating a bacterium belonging to the genus Streptomyces, capable of producing the titled substance, in a medium. CONSTITUTION:A strain such as Streptomyces sp. SF2080(FERM-P 5072), etc. belonging to the genus Streptomyces, capable of producing a novel antibiotic pyrrolomycin E is cultivated in a medium containing a well-known carbon source, nitrogen source, inorganic salt, etc. The cultivation is carried out under aerobic conditions by submerged culture at 25-34 deg.C, and the production and accumulation of pyrrolomycin E is maximized for 2-7 days both by shaking culture and tank culture. Extraction is carried out with stirring by adding a solvent such as ethyl acetate, etc. to the filtrate of the culture, and the solid substance is blended with acetone, etc. to give an active ingredient, which is extracted with ethyl acetate, etc. The extracted solutions from the filtrate and the solid substance are combined, the solvent are removed, and pyrrolomycin E is obtained by column chromatography, recrystallization, etc.
Patients were eligible for enrollment if they had received a clinical diagnosis of Meniere's disease according to the 1995 AAO-HNS criteria (Committee, 1995). These criteria can be briefly described as follows: 1) Repeated attacks of vertigo: A definitive spell is spontaneous vertigo lasting at least 20 minutes. A mixed type of spontaneous nystagmus is observed during attacks. 2) Fluctuating cochlear symptoms: The hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range.
A system selects a user profile based on biometric information. A wearable device is provided with one or more sensors that detect or measure user biometric information selected from of at least one of, a user's activities, behaviors and habit information, and a user's health. The wearable device includes circuitry that provides at least identification of the wearable device, a communication system, and a pathway system. A telemetry system is in communication with the wearable device. The telemetry system includes a database of user profiles. The telemetry system uses one or more processors to compare received biometric information from the wearable device, perform a comparison, and determine a user profile stored in a database. The telemetry system selects records of user biometric data of one or more users.
NEW MATERIAL:A compound expressed by formula I (M is Zn, Ca, Mg, Al or Zr; n is the valence of M). EXAMPLE:Zinc p-dimethylaminobenzoate. USE:An ultraviolet light inhibitor, useful as an antisuntan agent and a base for cosmetics, and having improved ultraviolet light absorption ability and antisuntan effect without irritation to the skin. PREPARATION:An aqueous solution of a water-soluble multivalent metallic salt expressed by the formula M(X)n (X is Cl, NO3, SO4 or CH3COO) is added to an aqueous solution of an alkali salt of p-dimethylaminobenzoic acid expressed by formula II (A is Na, K or NH4) under agitation. When the pH of the system becomes 8.5, an aqueous solution of an alkali is added to adjust the pH to 8.5- 9.0. The reaction is carried out to afford the aimed compound expressed by formula I .
The present invention provides medicine for treating arthritis in an immersion mode, which is characterized in that the medicine is a mixture comprising 90 to 100 units of energy compound agent, 70 to 80 mg of compound bone peptide, 75, 000 to 80, 000 units of gentamicin and 5 to 6 mg of 2% lidocaine. The medicine of the present invention is used for treating the articular cavity and the bursa synovialis in an immersion and injection mode so that the medicine can directly reach affected histocyte and is combined with receptors for supplementing cell energy and activating the metabolism of cells. Therefore, the activity and the permeability of ectocellular enzymes are improved, acute and chronic non-specificity inflammatory reactions are resisted, damage of pathogenic factors to histiocyte is inhibited and prevented, and partial inflammatory reactions are eliminated. Finally, the medicine performs functions by means of energy coupling. Experiments in clinical application show that the medicine has the advantages of no side effect, reliable curative effect and high cure rate. The medicine has obvious curative effects on arthritis on the vertebral column and limbs.
Atrial fibrillation (AF) is the most common sustained arrhythmia in adults. Current limitations of pharmacological and ablative therapies motivate the development of novel therapies as next generation treatments for AF. The arrhythmia mechanisms creating and sustaining AF are key elements in the development of this novel treatment. Gene therapy provides a useful platform that allows us to regulate the mechanisms of interest using a suitable transgene(s), vector, and delivery method. Effective gene therapy strategies in the literature have targeted maladaptive electrical or structural remodeling that increase vulnerability to AF. In this review, we will summarize key elements of gene therapy for AF, including molecular targets, gene transfer vectors, atrial gene delivery and preclinical efficacy and toxicity testing. Recent advances and challenges in the field will be also discussed.